HONG KONG, Aug 31, 2024 - (ACN Newswire via SeaPRwire.com) - GF Securities Co., Ltd. ("GF Securities" or the "Company", together with its subsidiaries within the scope of its consolidated financial statements (“subsidiaries”), the “Group”; HKSE: 1776; SZSE: 000776) announced its interim results for the six months ended 30 August 2024 (the “Reporting Period”). During the Reporting Period, under the guidance of the Board of Directors, the management of the Company led all staff to carry out key work to focus on enhancing core business capabilities, cultivating new quality competitiveness, improving comprehensive service capabilities and boosting resource allocation efficiency, as a result of which, the Company’s operating results achieved stable development with a total revenue and other income of RMB17,136 million, and a net profit attributable to owners of the Company of RMB4,362 million. As of 30 June, 2024, the Group’s total asset amounted to RMB689,328 million, representing an increase of 1.05 % as compared to the end of 2023 ; and equity attributable to owners of the Company amounted to RMB140,703 million, representing an increase of 3.67% as compared to the end of 2023.As one of the first batch of pilot comprehensive management brokerages selected by the CSRC, GF Securities possesses licenses for a full range of services involved in four business segments, including investment banking, wealth management, trading and institution, and investment management. The Group has successively set up futures subsidiaries, public fund subsidiaries, private fund subsidiaries, alternative investment subsidiaries and asset management subsidiaries. With its unique value concept and pragmatic entrepreneurial style, the Company has built up a full-service chain with comprehensive layout and strong strength. In respect of regional development, the Company based in Guangdong and serves the whole country, connecting domestically and internationally, forges a leading national brokerage with a long-term vision and an open mind. Against this backdrop, the Company has maintained main operating indicators ranking among the top securities companies in China for many consecutive years, and established its leading advantages in various key business segments.Wealth Management Business Continues to Lead under Ongoing and Deepening TransformationThe Company has taken the lead in proposing wealth management transformation and has currently been equipped with excellent financial product research, sales capabilities and professional asset allocation capabilities. The Company had more than 4,400 securities investment advisors, ranking No. 1 in the industry (in terms of parent company caliber), striving to provide precise wealth management services to different clients.In the first half of 2024, the Company focused on strengthening the construction of investment research and professional investment & advisory service capabilities, continuing to build a differentiated product and service supply system, and promote the transformation of wealth management business into an investor-oriented buy-side investment advisory business to enhance investors’ sense of gain. In the domestic market, as of the end of June 2024, the total balance of financial products sold by the Company on a commission basis exceeded RMB220 billion, representing an increase of 4.00% as compared to the end of last year while the sales amount of financial products on the Yitaojin E-commerce platform (including Cash Return and Taojin Market amounted to RMB116.918 billion. In the overseas market, the Group further diversified its product offerings and continued to transform into wealth management with net sales income and balance of financial products and commissions for multi-market transactions achieving a year-on-year growth. In addition, the market share (in terms of trading volume and trading amount of futures) of GF Futures, the wholly-owned subsidiary of the Group, achieved year-on-year growth. GF Futures (Hong Kong) was awarded the Most Active Chinese Commodity Futures Broker of 2023 by the Singapore Exchange.At the end of June 2024, the Company had 356 branches and business departments nationwide, with a presence in 31 provinces, municipalities, and autonomous regions across the PRC. The number and coverage ratio of business outlets in the nine cities of the Pearl River Delta in the Guangdong-Hong Kong-Macao Greater Bay Area ranked No. 1 in the industry, providing a wide range of market reach for the Company’s business and laying important support for customer accumulation and service.Continuous Development of Insitutional Business with Outstanding Research Capabilies EmpowermentThe Company actively seizes the opportunities of reform on the investment, financing and trading, gives full play to the role of research in empowering and promoting the Company's core business, integrates resources to provide comprehensive solutions for institutional customers, improves institutional customer service capabilities and institutional customer service systems, and continues to expand institutional business.In the first half of 2024, the market-making business of the Company continued to be in the first echelon of the market, providing market-making services for more than 700 funds and all ETF options of the SSE and SZSE, and market-making services for CSI 300 stock index options and CSI 1000 stock index options of the China Financial Futures Exchange. The Company issued 44,559 private equity products through the China Securities Inter-agency Quotation System and OTC market, with a total amount of RMB338.330 billion. The Company became the lead market maker for stock index options of the China Financial Futures Exchange, and was granted the SSE’s 2023 Stock Option Market Development Contribution Award (Outstanding Option Market Maker Award and Contribution to New Option Varieties Award), the SZSE’s 2023 Outstanding ETF Liquidity Provider Award and Outstanding Option Market Maker Award, and the CFFEX’s 2023 Outstanding Stock Index Option Market Maker Award (Bronze Award). As the end of June 2024, the Company provided market-making services to 47 NEEQ enterprises while its bond market-making business created the “GF Securities Pearl River Delta ESG Sustainable Development Local Debt Basket ” to help market institutions actively participate in the green economy construction and sustainable development in the Pearl River Delta through portfolio investment.At the same time, as a primary dealer of OTC derivatives business with professional advantages in derivatives pricing and trading, the Company continued to strengthen the construction of team and system, enhanced product creation, strategy innovation and trading and sales capabilities, and diversified and expanded its product system, types of underlying products and revenue structure, so as to continuously provide institutional customers with asset allocation and risk management solutions through OTC derivatives.The Group continued to promote the research-driven business model and gave full play to the empowerment and promotion effect of research on the Company’s core business. As of the end of June 2024, the Group’s equity research covered 28 industries and 993 A-share listed companies in mainland China, and 154 Hong Kong and overseas listed companies. The Company achieved research results based on digital means such as GF research portal and mini programs, continued to explore in the direction of intelligence, and strived to build a multiplatform, multi-channel and multi-dimensional customer service system. During the Reporting Period, the industrial research institute of the Company continued to build an ecosystem of production, learning, research, investment and financial integration, empowered the development of various business segments, provided research support for policy formulation and industrial planning of government departments, and explored the establishment of industrial incubation and transformation cooperation mechanism with key scientific research universities to play a role as a bridge of “technology-finance-industry.The outstanding research capacity of the Company enjoys a high reputation in the industry and received numerous honors. The Company has received the New Fortune Domestic Best Research Teams and the New Fortune Most Influential Research Institution for consecutive years from 2017 to 2023, and Top 5 Golden Bull Research Institution award by China Securities Industry Analyst Golden Bull Award for consecutive years. Meanwhile, it ranked in the forefront in the selection of Sell-side Analyst Crystal Ball Award , Best Analyst of Shanghai Securities News, the Golden Kirin Best Analyst of Sina Finance and the Gold Analysts of the 21st Century .Continuous Improvement of Investment Banking Business with Outstanding FunctionalitiesGuided by customer demand, the Company has built an investment banking service system with a full business chain throughout the life cycle. During the Reporting Period, the Company actively implemented the national strategies and regulatory policies by adhering to the fundamental purpose of serving the real economy with finance and giving priority to functionality; focused on serving the development of new productive forces and national strategic emerging industries by deeply exploring “specialized, sophisticated, distinctive and innovative” enterprises and effectively fulfilled its responsibility as a “gatekeeper” in the capital market.In respect of domestic equity financing, as of the end of June 2024, the Company sponsored 43 companies listed on the NEEQ as the lead brokerage, of which 76.74% were “specialized, sophisticated, distinctive and innovative” enterprises. In respect of overseas equity financing, the Company completed two Hong Kong IPO projects including one IPO project as a sponsor with an issue size of HK$1.046 billion, ranking third in the market; completed two refinancing projects with an underwritten amount of HK$4.881 billion; and its equity financing business in Hong Kong ranked third among Chinese-based securities companies in terms of the total issuance size of IPOs and refinancing projects equally distributed among all underwriters, according to the statistics of Dealogic.In respect of bond and financing business, the Company attached great importance to serving national strategies and facilitated technological innovation enterprises to develop new productive forces; steadily enhanced its market position through leveraging the Group’s synergistic advantages, consistently expanding key regions, strengthening internal assessment mechanism and other measures, on the basis of a strict control of business development risk; and actively practices ESG to promote the green and lowcarbon development through bond and financing business. During the Reporting Period, the Company acted as the lead underwriter for 293 tranches of bonds, representing a year-on-year increase of 70.35%, with a lead underwritten amount of RMB152.428 billion, representing a year-on-year increase of 64.63%; acted as the lead underwriter for 52 tranches of various science and technology innovation bonds with an underwritten amount of RMB19.128 billion; and acted as the lead underwriter for 4 tranches of various low-carbon transformation and green bonds with an underwritten amount of RMB1.088 billion. In respect of Chinese offshore bond business, 33 bonds were issued with an underwritten amount of US$5.617 billion.In respect of financial advisory business, centered around the guidance of national industrial policies, financial policies and regional development policies, the Company practiced the business model of “One Guangfa” by holding a forum on merger and acquisition of new productive forces and building a merger and acquisition business ecosystem to provide customers with multi-level and all-round comprehensive services, promoting the orderly circulation of assets and capital. During the Reporting Period, the Company completed two projects in major asset restructuring and financial advisory business that had industry and regional influence, involving a total transaction amount of approximately RMB12.851 billion; and completed one overseas equity transaction, involving a transaction amount of approximately HK$1.098 billion. Two transactions in which the Company acted as buyer’s financial advisor were awarded the 2023-2024 Top Ten Domestic M&A Golden Whistle Award.In the future, GF Securities will continuously commit to its corporate values of “inquisitiveness and integrity” and carry forward its excellent cultural genes of an “army of doctors”, with knowledge as the guarantee and professionalism as the cornerstone, continue to deepen and consolidate the Company 's outstanding location advantage in the Guangdong-Hong Kong-Macao Greater Bay Area and other places, deploy long-term strategies to well develop business with higher standard, accelerate high-quality development and contribute to serving the real economy. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - Legend Holdings Corporation (“Legend Holdings” or the “Company”, Stock Code: 3396. HK) announces the unaudited condensed consolidated interim results of the Group for the six months ended 30 June 2024 (the “Reporting Period”). In the first half of 2024, adhering to high-quality development driven by technological innovation, Legend Holdings prioritized stability while pursuing progress, responded to changes in macro factors, strived to develop new quality productive forces, and the Company’s core competitiveness was steadily improved. During the Reporting Period, the Company recorded revenue of RMB233.4 billion, representing a 16% year-on-year increase, with net profit increasing to RMB2.805 billion. The net profit attributable to equity holders of the Company was RMB286 million, and this year-on-year decrease recorded was primarily due to the increasing complexity and uncertainty of global economy, which had impacts on profits contributed by diversified-industries operation segment as well as the investment business of industrial incubations and investments segment.During the Reporting Period, Legend Holdings continued to drive industrial innovation through sci-tech innovation, emphasizing new quality productive forces as a key focus for the enterprise’s high-quality development, expanding its presence in frontier industries such as artificial intelligence, biopharmaceuticals, advanced materials and new energy, while exploring emerging frontiers and achieving positive outcomes in building up modernized industrial system. The Company has been committed to increasing its investment in technology development and innovation, with accumulated R&D investments increasing 3.4% to RMB7.3 billion. Lenovo Group, a subsidiary of Legend Holdings, achieved milestone breakthroughs in strategic products, including the launch of the first AI PCs worldwide and several AI servers. Meanwhile, the Legend Holdings Family Group has stepped up developments in frontier industries such as advanced materials, innovative drugs, biomanufacturing, and commercial space. Legend Holdings has also made forward-looking investments, making early moves in new sectors such as quantum technology and life sciences, which are expected to become the growth drivers for new quality productive forces. During the Reporting Period, Legend Holdings has invested in nearly 40 technology projects, and to date, the Company has invested in a total of 120 national specialized and innovative “little giant” enterprises, maintaining an industry-leading position.Legend Holdings has always been committed to serving national strategic needs and actively promoting the high-quality development of the manufacturing industry chain. By advancing new industrialization and boosting China’s strategic strength in manufacturing, and digital development, Legend Holdings has promoted the intelligent transformation and upgrading of China’s manufacturing industry. Currently, 90% of China’s top 500 manufacturers, over 1,000 leading manufacturing enterprises, and more than 2,000 growth manufacturing enterprises have received support from the Legend Holdings Family Group. Meanwhile, funds under the management of Legend Holdings have invested over RMB20 billion in the manufacturing sector, promoting the listing of dozens of manufacturing enterprises and fostering about 20 niche-sector leaders in the industry. As the world’s leading AI full-stack product portfolio and solution service provider, Legend Holdings has intensified its efforts to expand its footprint in AI and promote AI applications and built a vibrant AI+ application ecosystem with cumulative investments in over 250 AI-related companies. Meanwhile, Legend Holdings has actively promoted the industrialization of digital sectors and digital transformation of various industries. This includes supporting the proactive construction of digital infrastructure, and building a nationwide integrated computing power network to advance the deep integration of the digital economy with the real economy.Legend Holdings has always insisted on integrating the green concept into its high-quality development and actively fulfilled its social responsibilities. Lenovo Group was the first domestic high-tech manufacturer to pass the Science Based Targets initiative (SBTi) net-zero target validation, and its MSCI ESG rating remains at AAA, the highest rating in this assessment. A number of green industrial projects newly laid out by Levima Advanced Materials were completed in the first half of the year, and multiple projects are scheduled to be completed and put into production in 2025. ZQET Group is expanding in the photovoltaic industry. It has invested in a 20GW N-type high-efficiency solar cell smart manufacturing project, with the first phase already in operation and its core products ranking among the top tier of the industry. Meanwhile, Legend Holdings focuses on systematic planning and long-term investment in public welfare areas such as “rural revitalization”, “innovative technology” and “promoting righteousness”, and has been keeping contributing Legend's value to the society.In the face of challenges and opportunities, Legend Holdings will continue to deepen the high-quality development led by scientific and technological innovation. While strengthening its industrial foundation and optimizing the resource allocation, the Company will expand its presence in frontier areas, cultivate emerging and future industries, further focus on new quality productive forces, and build its new core competitiveness. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - On 28 August 2024, Fosun International (HKEX: 0656) announced its 2024 interim results. During the reporting period, its revenue continued to grow, reaching RMB97.84 billion. Industrial operation profit maintained growth, reaching RMB3.47 billion, and profit attributable to owners of the parent was RMB720 million.Guo Guangchang, Chairman of Fosun International, said at the results presentation on the morning of 29 August, “In the first half of the year, although the macro environment remained challenging, we resolutely executed our strategy of focusing on core businesses, developing industry-leading companies and products in the industries where we have formed advantages. Such strategy has been proven effective in general. Looking ahead, we will remain focus on innovation and globalization, while focusing on asset-light operations, driving long-term development with competitive core strengths.”Since the beginning of 2024, the domestic economic recovery has been rocky and the international market has remained volatile, which has brought challenges to Chinese companies including Fosun. Fosun steadfastly pushed forward its strategic focus, driving development with core strengths, achieving quality and efficiency improvement in core industries, and maintaining a solid asset base.Analysts believe that, based on Fosun’s interim results, Fosun’s focus on the core industries in the household consumption sector and its proactive approach to driving innovation and globalization have further reinforced its business foundation, resulting in predictable stable profits. Additionally, over the past two years, Fosun has actively pursued asset-light operations, optimized asset portfolio, and continued to reduce leverage. These efforts have resulted in abundant cash reserves and a stronger financial cushion, which are expected to prompt the market to reassess Fosun’s value.Staying ahead in globalization and innovation, reinforcing business foundation to develop industry-leading companies and products In the first half of the year, Fosun’s four core subsidiaries, namely Fosun Pharma, Yuyuan, Fosun Insurance Portugal, and Fosun Tourism Group (“FTG”), achieved total revenue of RMB72.17 billion, accounting for 74% of the Group’s total revenue. Fosun’s strategy of focusing on core businesses has shown increasing benefits, with its advantages in core industries such as pharmaceuticals, tourism, consumption, and insurance continue to be strengthened.With years of effort in the aforementioned sectors, Fosun has developed a number of industry-leading companies and products.For example, in the first half of this year, Fosun Pharma, which ranks second among the top 100 pharmaceutical companies in China, was selected as one of top 20 global pharmaceutical companies in terms of pipeline scale for the third consecutive year. Shanghai Henlius is the first Chinese profitable innovative biopharmaceutical company listed in Hong Kong, with multiple independently developed monoclonal antibody biosimilars that are driving the rapid development of China’s biopharmaceutical industry. Its first blockbuster product, HANLIKANG, is the first domestic biosimilar approved for marketing. Fosun Insurance Portugal holds the largest market share in the Portuguese insurance market and ranks among the leaders in the insurance sector across Portuguese-speaking regions globally. Easun Technology, in the intelligent manufacturing segment, is a global leading automation and digitalization company.In addition, in the Happiness business segment, Club Med, a subsidiary of FTG, is the global leader that offers exquisite “all-inclusive” holidays. Atlantis Sanya is the leading integrated high-end tourism destination in China, helping to usher Hainan tourism into the 3.0 era. Laomiao Gold, a subsidiary of Yuyuan, is a China time-honored brand and a nationally renowned jewelry brand. These industry-leading companies and products have helped Fosun consolidate its leading position in related sectors.For Fosun, steady and profitable growth is driven by two factors: innovation and globalization.Amid the current domestic economic “involution”, “going global” has become a “must-do” for businesses. Fosun, which began its globalization journey as early as 2007, has become one of the benchmark global companies rooted in China. It has also established a profound industrial presence in more than 35 countries and regions worldwide.During its 17-year globalization journey, Fosun has achieved many successful projects and faced various challenges. Most importantly, this experience has allowed Fosun to develop globalization capabilities that rare among domestic companies. In addition, it has allowed Fosun to connect different markets, industries, and resources globally, achieving global presence, operations and development, while continuously enhancing its global operation capabilities.This is further illustrated by the following data, the Group’s overseas revenue for the first half of 2024 reached RMB45.87 billion, representing a year-on-year increase of 4%, and accounting for 47% of total revenue. Nearly half of the revenue came from overseas, which is rare among Chinese companies.More importantly, Fosun has actively driven the empowerment and synergy of its corporate ecosystem in the course of globalization. Its domestic and overseas member companies have made significant progress in global research and development (R&D), business expansion, operations, and investment and financing.For example, HANQUYOU, independently developed by Fosun’s subsidiary Shanghai Henlius, received marketing approval from the United States (U.S.) Food and Drug Administration (FDA), making it a “Chinese” monoclonal antibody biosimilar approved in China, the European Union (EU), and the U.S. HANLIKANG, China’s first biosimilar, received marketing approval from the Peruvian General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru, making it the third self-developed drug of Shanghai Henlius to be approved for overseas marketing after HANQUYOU and HANSIZHUANG.Moreover, Club Med, a subsidiary of FTG that operates 67 resorts worldwide, achieved a record-high business volume of RMB8.89 billion in the first half of 2024, representing a year-on-year increase of 10.3%. Club Med’s business in the Europe, Middle East and Africa (EMEA) region and the Americas continued to grow, and its business in Asia-Pacific region recovered significantly. In May 2024, Club Med signed an agreement in Oman for the launch of its first resort in the Middle East.Fosun Insurance Portugal, which began its operations in Portugal, has been actively expanding into overseas markets. In the first half of 2024, it achieved business growth domestically and internationally. The contribution from overseas markets further increased, with international business recording premiums of EUR885 million, accounting for over 30% of the total premiums; the net profit of international business was approximately EUR51 million, accounting for over 40%.Easun Technology, a global leading automation and digitalization company under Fosun, has also been advancing its overseas expansion. In the first half of 2024, it achieved new overseas orders of RMB3.99 billion, with a significant increase in orders from the U.S. market, reaching RMB750 million, more than doubling year-on-year.Innovation is also a core competence that Fosun has accumulated over a long period of time and has always adhered to. During the reporting period, Fosun invested a total of RMB3.5 billion to deepen its technological and innovation capabilities. Its integrated innovation model under a global vision has become more mature, resulting in a number of ground-breaking achievements that are steadily generating profits and driving Fosun’s growth.In terms of innovative drug R&D, Fosun Pharma has 4 products with a total of 9 indications were approved for marketing; 4 products with a total of 9 indications had entered the pre-launch approval stage/key clinical stage; and 9 products (by indication) have been approved to conduct clinical trials. Shanghai Henlius’ independently developed and manufactured innovative biologics continue to make breakthroughs. The world’s first anti-PD-1 monoclonal antibody for the first-line treatment of small cell lung cancer (SCLC), HANSIZHUANG, has been approved for 4 indications, benefiting over 75,000 patients. It has also been out-licensed to over 70 countries and regions, including the U.S., Europe, Southeast Asia, the Middle East, and North Africa. In addition, the new indication for SUKEXIN, a new generation of oral thrombopoietin receptor agonist (TPO-RA), has been approved by the National Medical Products Administration (NMPA).New progress has also been made in the deployment of cutting-edge medical devices and innovative therapies. In June 2024, Intuitive Fosun Headquarters Industrial Base was inaugurated in Shanghai. It is the largest integrated R&D, production and training base of Intuitive Surgical in the Asia-Pacific region, significantly accelerating the localization of the da Vinci surgical robot. Intuitive Fosun’s Ion robotic bronchoscopy was approved by the NMPA in March this year and was launched in July 2024.“Asset-light operations” taking shape, poised for revaluationBenefitting from the strong support in its business operations, Fosun’s financials have also continued to improve. During the reporting period, Fosun continuously optimized its asset portfolio, continuously reduced leverage, and maintained a sound financial position. As of 30 June 2024, the Group’s adjusted total debt-to-capital ratio was 50.2%, maintaining a downward trend since 2020. Adjusted NAV was HK$17.4 per share, indicating that Fosun International’s current share price is significantly undervalued.Meanwhile, Fosun has actively strengthened its financial cushion and maintained ample cash reserves. As of 30 June 2024, Fosun International’s cash and bank balances and term deposits reached RMB109.55 billion, representing an increase of RMB17.1 billion compared to the end of 2023. In the 17 years since its listing, Fosun has accumulatively paid out HK$25.6 billion in dividends, with the dividend payout ratio gradually increasing to over 20% in the past five years.In June 2024, the international rating agency S&P fully recognized the effectiveness of Fosun’s financial strategy and affirmed its rating outlook as “stable”.While achieving stable profits through ongoing innovation and globalization, Fosun has also responded to the new market environment by streamlining its business. It has progressively exited some non-core industries and has actively advanced its asset-light strategy, which is now taking shape.In May 2024, Fosun sold all of its 99.74% stake in the German private bank HAL, which attracted market attention. After the completion of the transaction, Fosun will no longer hold any shares in HAL, but will retain the HAFS asset servicing business, managing approximately EUR100 billion in assets in an asset-light operation model.In the tourism sector, Fosun’s asset-light operation model has achieved remarkable results, with IPs such as Club Med, Atlantis Sanya, and Taicang Alps becoming benchmarks in the domestic tourism industry. In the first half of 2024, 85% of Club Med resorts adopted a leasing and management model, with the proportion of self-owned resorts declining to 15%.In April 2024, the AMAZE Snow Mountain Camp, FTG’s new IP in Lijiang Club Med Resort, quickly became a hit after its opening, driving significant occupancy increases at the nearby Club Med Lijiang Resort and Joy Holiday Hotel Lijiang.In June 2024, FTG joined hands with the Taicang Municipal Government to build the phase II of Taicang Alps Resort, a one-stop ice and snow-themed urban tourist destination. The phase II project, with a total investment of over RMB5 billion, is funded by the Taicang Municipal Government and operated and managed by FTG. The successful operation of the Alps Snow Live has provided confidence and momentum for the phase II project, which is expected to set several world records in ski resorts.Fosun has also joined hands with partners to set up a number of industry funds to drive the future of advantageous industries. In March 2024, leveraging its leading advantages in biomedicine, Fosun Pharma joined hands with Shenzhen Guidance Fund and seven other investors to jointly establish a RMB5.0 billion biomedical industry fund, with all proceeds to be invested in biomedical, cells, genes, etc. Shanghai Fujian Equity Investment Fund Management, a subsidiary of Fosun Pharma, was selected through public selection process in Shenzhen to exclusively manage this fund. In April this year, the Shenzhen Municipal Government and Fosun signed a strategic cooperation framework agreement, both parties will further strengthen cooperation in areas such as biomedicine, cultural and sports tourism, and fashionable consumption.In addition, Fosun Capital, together with Wuhan Innovation Investment and Wuhan Fund, established a RMB3.0 billion industry fund with an initial scale of RMB1.1 billion in April 2024. This is the first batch of market-oriented fund invested by Hubei Province since the establishment of the RMB20.0 billion government guidance fund, mainly focusing on the four major sectors of new generation information technology, dual carbon, intelligent manufacturing, and consumption.Given the current market environment, it is expected that Fosun will continue to focus on asset-light operations, continuously expand its “circle of friends”, strengthen in-depth cooperation with all parties, and achieve win-win results through complementing each other’s advantages.Market analysts believe that Fosun has achieved sustained and stable profits leveraging its core strategies of innovation and globalization. In addition, by exiting non-core assets, pursuing asset-light operations, and continuously reducing debt, Fosun has maintained robust financial health, paving the way for a potential market revaluation.Guo Guangchang believes that in the future, investors will place greater emphasis on the growth of core industries and the stability of cash flow. “One-off asset sales are only short-term solutions. The growth of core businesses is crucial for a company to achieve stable profits.” Fosun aims to build a consumer group centered on core industries, ensuring more predictable business development and profits. At both the group level and within each business unit, Fosun is committed to creating value for its customers and investors that is manageable in terms of risk and promotes steady growth. Copyright 2024 ACN Newswire via SeaPRwire.com.

- Dorzagliatin (trade name: HuaTangNing, world's first dual-acting glucokinase activator (GKA), successfully entered China’s National Reimbursement Drug List for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (the “NRDL”) at the end of 2023. Hua Medicine worked with sales promotion partner Bayer Healthcare Company Limited (“Bayer”) and 80 Tier 1 distributors to begin the pharmaceutical market entry in 31 municipalities and provinces in China.- The new NRDL became effective on January 1, 2024. In the first half of 2024, the sales volume of dorzagliatin increased significantly. As of June 30, 2024, sales of HuaTangNing reached 846,000 packs with a sales revenue of RMB102.7 million. The sales revenue increased by 46%, compared with the six months ended June 30, 2023.- Dorzagliatin experienced a fast entry into hospitals, especially in Shanghai, Beijing, Tianjin where the government policies support market entry for novel new drugs. By the end of June 30, 2024, dorzagliatin was prescribed in over 2,100 hospitals and over 2,900 pharmacies. Dorzagliatin was sold principally through hospitals (approximately 72% of total sales), with the remainder of sales through pharmacies (20%) and internet drug stores (8%).- Gross profit in the first half of 2024 is RMB47.8 million, representing a gross profit margin of 46.5%. Bank balances and cash position increased by 51.9% to approximately RMB1,338.8 million for the six months ended June 30, 2024, compared with the six months ended June 30, 2023.- Dorzagliatin manufacturing capacity continues to expand, with the expectation to reach 3 million packs in 2024. New processes for larger capacity have been established with our partners and are under regulatory review for production permit.- Post marketing clinical studies proceeded at an accelerated rate, in which HMM0601 enrolled 1,368 patients and HMM0701 enrolled 102 patients. HMM0601 is designed to evaluate the long-term safety of dorzagliatin by collecting 1-year clinical safety data in 2,000 T2D patients and HMM0701 is a prospective real-world study to explore dorzagliatin’s clinical beneficial effects on the improvement of glucose homeostasis, cognitive function and diabetes remission. A good drug safety profile for dorzagliatin has been observed since its commercial launch in October 2022 – a time span of over 20 months and approximately 100,000 patient exposure.- Two Mendelian randomization studies conducted by our collaborating Hong Kong-based clinical investigators, and published in Cardiovascular Diabetology showed that glucokinase activation can lead to long term benefits in reduction of risks in cardiovascular diseases and dyslipidaemia. New clinical indications shall be further explored with our commercialization partner.HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company’s business progress for the first half of the year and business outlook.Dr. Li Chen, the founder and CEO of Hua Medicine, said, “The first half of 2024 marks a milestone for the commercialization efforts of Hua Medicine. Dorzagliatin's successful inclusion in China’s National Reimbursement Drug List has significantly improved patient accessibility and affordability. Against the backdrop of comprehensive support from the national and local governments for the development of the biopharmaceutical industry, and with the joint efforts of the Company, commercial partners, and production partners, the production capacity of dorzagliatin is rapidly increasing, accelerating its entry into hospitals and pharmacies nationwide to benefit more patients. With the continued growth in the number of users, the safety of dorzagliatin has been well validated, and its economic and social benefits have also greatly increased, instilling confidence in the Company's future development. Through sales expansion and operational optimization, we hope to achieve profitability for the Company by 2025. Currently, Hua Medicine is also conducting basic and clinical research on dorzagliatin globally, aiming to continuously expand its indications and target populations, explore new disease areas, and promote human health and well-being.”Progress of Clinical Research and Company Operations- During the first reporting period under the NRDL, dorzagliatin experienced a fast entry into hospital and pharmacies, especially in Shanghai, Beijing, Tianjin where the government policies support market entry for novel new drugs. The number of hospitals prescribing dorzagliatin exceeded 2,100 in the first half of 2024.- Revenue of dorzagliatin reached RMB102.7 million in the first half of 2024 and is expected to continue to grow in the second half of 2024. As we build off our new foundation under the NRDL, we plan to leverage our well-established partnerships to enhance the dorzagliatin manufacturing process, which is expected to lead to efficiencies, expanded capacity and reduction of cost of goods.- We continued our post marketing clinical studies at approximately 80 hospitals to better understand the benefits dorzagliatin provides to patients with Type 2 diabetes and T2D complications, such as memory loss and diabetes kidney disease. Through our collaboration with our clinical research partners in Hong Kong, we have discovered that glucokinase (GK) activation may bring the benefits of reduction of risks in cardiovascular disease, and dyslipidemia. These results (applying the Mendelian Randomization (MR) methodology) certainly expand our understanding of the benefits of GK activation through dorzagliatin and for uncovering new indications of dorzagliatin in the future. Mendelian Randomization (MR) is a statistical method that uses genetic variants to investigate the causal effects of exposures (e.g., treatments) on outcomes (e.g., diseases). Its unique advantage lies in its reduced susceptibility to confounding and time-related biases compared with observational studies, which is achieved by leveraging the random allocation of genetic variants at conception. In evidence-based medicine, the credibility of evidence from MR is considered to be among the highest, second only to that of randomized controlled trials.- We have advanced our post-marketing real world evidence (RWE) studies HMM0601 and HMM0701 in T2D patients in China, and HMM0123 in Hong Kong, China. In these studies, we are collecting evidence in medical practices for optimization of glucose homeostasis either through dorzagliatin alone or in combination with standard care T2D medications such as metformin, DPP-IV inhibitors, SGLT-2 inhibitors, GLP-1RA and insulin. These results create new evidence for dorzagliatin in the expansion of its indication in diabetes prevention and remission.- We are continuing our drug development pipeline with focus on the fixed dose combination (FDC) of new drug candidates. The new drug Dorzagliatin-Metformin FDC entered manufacturing process validation and our plan is to launch this new medicine for Type 2 diabetes in 2028. Additional new FDC drugs with dorzagliatin will be developed for T2D patients, tailored specifically to address T2D patients with associated complications such as obesity and diabetes kidney disease.- To further leverage the unique advantage of dorzagliatin in restoring GLP-1 secretion in patients with diabetes and obesity, Hua Medicine initiated its Phase I study in the United States with our 2nd generation GKA. The trial has been proceeding smoothly and has already completed dose escalation in three cohorts of T2D patients in the United States. The topline data is expected to be available in the fourth quarter of 2024, supporting future drug development.- At the American Diabetes Association (ADA) Annual Meeting 2024, Hua Medicine reported new scientific data supporting the combination of dorzagliatin with a SGLT-2 inhibitor which led to improvement in glycaemic control. Combination of dorzagliatin with chronic kidney disease (CKD) medicine, such as SGLT-2 inhibitor, empagliflozin, in mid to late stage diabetes kidney disease patients, offers new opportunity to expand dorzagliatin’s indication.- We are exploring more drug repurposing opportunities for dorzagliatin using MR framework, such as renal diseases, neuropathy related diseases, eye related diseases, cognitive disorders, and cancers. Animal studies shall be further performed to validate the promising findings.- We are continuing to optimize our protein allosteric modulation technology (PAMT) and expansion from positive allosteric modulator (PAM), such as GK positive allosteric modulator dorzagliatin, to negative allosteric modulator (NAM) in kinase and G-protein-coupled receptors (GPCR) proteins. The GK NAM program advanced to the pre-clinical candidate (PCC) selection stage and final optimization of the PCC to clinical candidate for congenital hyperinsulinism (CHI), and potentially for dyslipidaemia. We continue to advance mGLUR5 NAM program for its clinical potential in Parkinson’s disease (PDLID), Fragile X syndrome (FXS), and drug addiction.Financial highlightsAs of June 30, 2024,- Bank balances and cash position was approximately RMB1,338.8 million.- Total revenue generated by the Company was approximately RMB102.7 million, reflecting sales of approximately 846,000 packs of HuaTangNing .- Total other income was approximately RMB55.1 million, of which approximately RMB47.8 million was attributable to the amortization of Bayer milestone income.- Total expenditures was approximately RMB245.9 million, of which approximately RMB119.8 million was attributable to research and development expenses.Forward-looking StatementThis article contains the statements regarding the future expectations, plans and prospects for Hua Medicine and the investigational product. The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect as a result of various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin on hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with varying degrees of renal function impairment (including end-stage renal impairment without dialysis). Hua Medicine partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing in China, benefiting diabetic patients and their families.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.comDisclaimerFor the accuracy and completeness of the context, references to information related to products launched in China, especially label or requirements, should follow the relevant documents approved by the Chinese regulatory authorities.The above information should not be interpreted as a recommendation or promotion of any drug or treatment regimen, nor should it substitute for the medical advice of any healthcare professional. Please consult a healthcare professional for any matters related to medical treatment. Copyright 2024 ACN Newswire via SeaPRwire.com.